November 15, 2007
Attn: Business Editors
For Immediate Release
The Largest Canadian-Owned Generic
Pharmaceutical Company
Acquires Topgen E.S.V. in Belgium from Zambon
Toronto, ON (November 15, 2007) — Apotex Inc., the largest
Canadian-owned generic company announced today the purchase from Zambon
of the pharmaceutical company, Topgen, E.S.V. of Belgium, No acquisition
price was disclosed.
Topgen, headquartered in Brussels, is the 7th largest generic pharmaceutical
company in this country with approximately 30 generic registrations and has a
nation-wide sales force that reaches over 4,000 doctors and 3,000 pharmacies.
The Belgian generic market is less developed than many other markets in Europe,
with about a 10% marketshare, but it continues to experience strong growth.
"This acquisition represents an important milestone for Apotex International
as it extends the organization’s footprint in Europe and will be a launching pad
for many E.U. products currently in the Apotex development pipeline", stated
Andrew Kay, Apotex International President.
"The sale of Topgen furthers Zambon's strategy of focusing its Belgian
operations on developing its portfolio of branded products, while simultaneously
strengthening our relationship with Apotex, which is already a partner of Zambon
and Chiesi in Italy through Doc Generici S.r.l.", explained Roberto Consonni,
CEO of Zambon' Pharma Business.
The Apotex Group of Companies has over 6,800 employees worldwide including
Canada and sales of over $1 billion annually. Apotex has planned R&D
expenditures of $2 billion over the next 10 years and has 600 products under
development. It exports its products to over 115 countries with Apotex
International having an affiliate presence in the Czech Republic, Mexico, New
Zealand, Australia, Poland, Turkey, Italy and India, as well as the U.K
Zambon Company S.p.A. is the holding company of the Zambon group of companies,
consisting of fine chemicals specialist ZaCh System, pharmaceuticals
multinational Zambon S.p.A and corporate venture specialist Z-Cube, which
supports young life science companies in bringing promising new therapies to
market. Zambon Company S.p.A., which was originally founded in 1906, coordinates
a group of more than 2,200 employees in 16 countries on three continents and
consolidated sales of approx. €500m. Zambon S.p.A., Italy's leading independent
pharmaceutical company, works in three main therapeutic areas - respiratory,
pain relief and women’s health, with a portfolio of innovative products.
-30-
For further information:
Apotex Inc.
Elie Betito
Director, Public & Government Affairs
416-749-9300, ext. 7366
Cell: 416-558-5491
ebetito@apotex.com
Zambon Group
Stefania Torelli
External Communication Dir.
+390266524040
Cell.+393482486070
stefania.torelli@zambongroup.com
|
|
